Sabby Management’s Perspective Therapeutics CATX Stock Holding History

Sabby Management’s Portfolio CATX Stock Details CATX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-37,061	Closed	-$152K	–	98
2019 Q2	$152K	Sell	37,061 -90,907	-71%	-$381K	0.19%	62
2019 Q1	$467K	Sell	127,968 -97,515	-43%	-$381K	0.22%	33
2018 Q4	$676K	Buy	225,483 +32,934	+17%	+$141K	0.15%	41
2018 Q3	$999K	Buy	+192,549	New	+$1.07M	0.13%	53
2014 Q2	–	Sell	-22,538	Closed	-$496K	–	264
2014 Q1	$496K	Sell	22,538 -39,615	-64%	-$403K	0.03%	178
2013 Q4	$311K	Sell	62,153 -104,157	-63%	-$549K	0.02%	169
2013 Q3	$1.08M	Buy	+166,310	New	+$1.04M	0.07%	118

Other funds holding CATX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HPWM

Highland Private Wealth Management Bellevue, Washington $620M AUM 18.88% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

CAG

Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

CWM

Cahaba Wealth Management Atlanta, Georgia $1.66B AUM 17.04% 1-Year Est. Return

Sabby Management's CATX Position: Q3 2019 in Review

Sabby Management sold out of Perspective Therapeutics (CATX) in Q3 2019, closing a stake of 37,061 shares — an estimated $152K sold.

Sabby Management first reported a position in CATX in Q3 2013 and held it in 7 quarters. The position peaked at $1.08M in Q3 2013. 30 funds tracked by Wall St. Rank hold CATX as of Q3 2019.

Sabby Management reported no remaining Perspective Therapeutics position as of Q3 2019 after selling out during the quarter.
Sabby Management sold 37,061 Perspective Therapeutics shares in Q3 2019, an estimated $152K.
Sabby Management first reported a position in Perspective Therapeutics in Q3 2013 and held it in 7 quarters.
Sabby Management's Perspective Therapeutics position peaked at $1.08M in Q3 2013.
30 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q3 2019.

Based on Sabby Management's 13F filing for Q3 2019, filed 15 Nov 2019.